Castration-resistant prostate cancer is a lethal disease. The cell type(s) that survive androgen deprivation remain poorly described, despite global efforts to understand the various mechanisms of therapy resistance. 
Introduction
Prostate cancer remains a major cause of cancer death, due to resistance to androgen deprivation therapy in advanced stages of the disease [1] . Despite global efforts to understand the mechanisms of androgen-deprivation resistance, the underlying aetiology remains incompletely understood. Prostate tumours are composed 52 L Sackmann Sala et al significant decline in luminal cell number, with little or no decline in basal cells [5] . The latter population is therefore considered to be castration-tolerant and to repopulate the epithelium when androgen signalling is restored [5] . In addition, recent studies have shown that the adult mouse prostate contains rare luminal-like cells with stem cell characteristics termed CARN (castration-resistant Nkx3.1-expressing cells) [6] and CARB (castration-resistant Bmi1-expressing cells) [7] that also survive castration. Finally, using human patient-derived xenografts (PDXs) of treatment-naïve prostatic tumours, we showed that a luminal [cytokeratin (CK) 8/18 + ] population of castrate-tolerant cells with stem-like properties survives androgen withdrawal. These cells remain quiescent upon androgen deprivation and regenerate tumours upon restoration of androgens [8] . Both in mouse and in human prostates, castrate-tolerant luminal cells exhibiting stem-like properties remain poorly characterized, as specific markers are yet to be identified.
We recently identified in wild-type (WT) mouse prostates a rare prostate epithelial cell population called LSC med (Lin − /Sca-1 + /CD49f med ) that displays luminal progenitor properties [9, 10] . This luminal-like (CK8 + , CK5 − ), stem cell antigen-1 (Sca-1)-positive, Nkx3.1-negative cell population generated 2D colonies and 3D spheres in androgen-free conditions. In addition, in agreement with their condition of luminal progenitors, LSC med lost Sca-1 expression upon androgen stimulation in vitro, suggesting differentiation to mature luminal cells [9] . LSC med from WT prostates can also generate organoids in vitro and prostate-like structures in vivo and survive androgen deprivation [11] . Of particular interest, we have also reported a marked amplification of LSC med in the premalignant prostates of Pb-PRL mice [9] . These transgenic mice display Stat5 overactivation in prostate luminal cells [12] , mimicking what is observed in human prostate cancer [13] .
The androgen-independent and progenitor characteristics of LSC med suggest their potential role in prostate tumourigenesis and in the progression to castrate-resistant prostate cancer (CRPC). However, very little is known about this recently discovered cell population, including their presence in prostate cancer. Here, we show that LSC med (i) are present and tolerate androgen deprivation in various mouse models of prostate tumourigenesis; (ii) represent, before and after castration, more than 80% of prostate epithelia in Pten pc−/− mice (a relevant model of CRPC), massively proliferate after castration, and have tumour-initiating capacity in vivo; (iii) exhibit a unique gene expression signature that distinguishes them from prostate cell populations designated as luminal and basal/stem cells [14] ; (iv) display intrinsically low activation of androgen receptor (AR) signalling consistent with their resistance to androgen deprivation; and (v) can be identified on prostate tissue sections by CK4 immunostaining. In all, this study identifies LSC med as a probable source of prostate cancer relapse after androgen deprivation and as a new therapeutic target for the prevention of CRPC.
Materials and methods

Animals
Pb-PRL mice (prolactin transgene driven by the short probasin promoter) were generated in the Paris laboratory on a C57BL/6 J background (> 20 backcrosses), as previously described [12] . Pten pc−/− mice (Pten loxP/loxP mice crossed with Pb-Cre4 transgenic males) were generated in the Vienna laboratory as described previously [15] and maintained on a C57BL/6 and Sv/129 mixed genetic background. Hi-Myc (ARR2/Pb-MYC) mice maintained on a pure FVB/N background were bred at Monash University. Experiments were performed using 6-to 8-month-old mice, i. 
Prostate subpopulation sorting by FACS
The procedures for cell sorting were performed as described previously by FACS using the antigenic profile Lin/Sca-1/CD49f [9, 16] . Cell sorting was performed on a BD FACSAria III (BD Biosciences, San José, CA, USA). A brief methodological summary is provided in the supplementary material, Supplementary materials and methods, and sequential gates and staining controls are shown in Figure S1 of the supplementary material. Sorted cells were collected in DMEM medium, supplemented with 50% FBS, glutamine, and penicillin-streptomycin, or in RA1 Lysis Buffer (Macherey-Nagel, Düren, Germany) to perform RNA extraction as described in the supplementary material, Supplementary materials and methods. more than 6.0 million probes covering coding transcripts (70% of probes) and non-coding transcripts (30% of probes). Prior to hybridization, cDNA was fragmented and biotin-labelled using the Encore Biotin Module (NuGEN) as recommended by the manufacturer. Biotinylated DNA fragments were hybridized onto the array chips using the Hybridization Wash Stain kit (Affymetrix). The chips were washed, stained, and scanned using the Affymetrix Model 450 Fluidics Station, the Affymetrix Model 3000 scanner, and the Command Console software for piloting the GeneChip systems. For data analysis, raw data CEL files were imported in R/Bioconductor using the Oligo package (http://www.r-project.org/). Expression levels were normalized using the RMA algorithm from the affy package and background noise was computed using a custom algorithm within R as follows. Assuming that a maximum of 80% of genes are expressed on any given microarray, we tagged the 20% of probes with the lowest intensity for each microarray as background. A threshold was fixed at two standard deviations over the mean of the background. All probes for which normalized intensities were lower than the computed threshold were designated as background for each array. When comparing gene expression levels between two groups, a probe was included in the analysis if its intensity exceeded the background in at least 80% of the samples from at least one group. Group comparisons were done using Student's t-test and lists were filtered at p < 0.05 and fold change >1.5. Cluster analysis was performed by hierarchical clustering using the Spearman correlation similarity measure and average linkage algorithm. Heatmaps were generated using Java Treeview [17] and a custom R script. Functional analyses were carried out using Ingenuity Pathway Analysis (IPA; Qiagen, Hilden, Germany). Microarray data have been deposited on the ArrayExpress site (accession number E-MTAB-4991) (http://www.ebi .ac.uk/arrayexpress). Data from transcriptomic studies available online on GEO were analysed using a strategy similar to that described above for our own transcriptomic data.
Reverse transcription-quantitative PCR (RT-qPCR)
For RT-qPCR, iTaq Universal SYBR Green Supermix (Biorad, Hercules, CA, USA) was used, and reactions were run on a Viia7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) or a qTower 2.0 Real-Time Thermal Cycler (Analytik Jena, Jena, Germany). Primers are listed in the supplementary material, Table S1 . Results were normalized to Eef1a1 expression.
Cytospins
Sorted cells were loaded onto the cytospin slide chambers of a Shandon Cytospin 2 (Thermo Scientific, Rockford, IL, USA) and centrifuged at 500 rpm at room temperature for 10 min.
In vivo regeneration assay
The in vivo prostate regeneration assay was performed as described previously [18] . In brief, 8 × 10 4 FACS-sorted LSC med cells (or basal/stem cells used as a control) harvested from three pooled Pten pc−/− prostates were combined with 1.5 × 10 5 urogenital sinus mesenchymal cells, mixed (1:1, v/v) with growth factor-reduced Matrigel (Corning, Corning, NY, USA) in a final volume of 150 μl, and injected subcutaneously into immunodeficient SCID male mice (Janvier, Saint Berthevin, France). Grafts were harvested 10 weeks later.
Immunohistochemistry/immunocytochemistry (IHC/ICC) and immunofluorescence (IF)
All samples were fixed in 4% PFA, paraffin wax-embedded, and sections underwent heat-induced antigen retrieval in citrate buffer at pH 6. IHC/ICC and IF were performed as described previously [9] using the antibodies listed in the Supplementary materials and methods (supplementary material), a Vector Elite ABC HRP kit with DAB substrate (Vector Laboratories, Burlingame, CA, USA), and haematoxylin as a counterstain. Slides were scanned with a Nanozoomer 2.0 (Hamamatsu, Massy, France) and analysed using NDP.view 2.5.14 software (Hamamatsu). For IF, nuclei were stained with Hoechst dye, and samples were analysed with a 10× or 20× objective under an Axio Observer.Z1 inverted microscope (Carl Zeiss Microscopy, Göttingen, Germany).
Statistics
Two-way analysis of variance (ANOVA) with Šídák's multiple comparison test was used to compare population percentages among intact and castrated mouse groups. Repeated measures one-way ANOVA tests were used to evaluate gene expression differences among the cell types for each genotype. Post-hoc multiple comparisons were performed using Tukey's test. Statistical analysis of transcriptome data is described in the corresponding methods section. A value of p < 0.05 was used as the significance cut-off for all tests. All analyses were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, San Diego, CA, USA).
Results
LSC
med are the most abundant epithelial cell type in intact and castrated Pten pc−/− prostate tumours
In humans, PTEN deficiency is observed in 69% of prostate cancer cases and up to 86% of CRPCs [19, 20] . Accordingly, prostate-specific Pten-deficient mice (Pten pc−/− ) develop invasive prostate adenocarcinomas [21, 22] . This model was therefore chosen to test the prevalence and androgen independence of LSC med in a cancer context. Strikingly, 82% of the whole Pten pc−/− epithelia of intact prostates was LSC med ( Figure 1A ). Since Pten pc−/− prostate tumours are castration-resistant [21] , we hypothesized that LSC med may tolerate castration, reflecting a role of these cells in the progression to castration resistance. Indeed, there was no change in LSC med prevalence in the castrated Pten pc−/− epithelium ( Figure 1A ). We also castrated Pb-PRL mice and observed that LSC med increased from 36% ( Figure 1B  and ref 9 ) to more than 70% of the epithelia before and after castration, respectively ( Figure 1B ). Wild-type mice served as controls, showing the expected low prevalence (< 10%) in intact prostates and a significant increase (> 20%) after castration ( Figure 1C and refs 9 and 11).
Together, these results demonstrate that LSC med are the most abundant epithelial cell population in malignant Pten pc−/− prostates, and they can survive androgen deprivation in all the models tested (normal, premalignant, and malignant prostate).
med are a unique prostate epithelial cell entity
To establish the cell identity of LSC med , we performed a microarray analysis of FACS-sorted LSC med , basal/stem, and luminal cell populations. This analysis was performed on WT prostates to circumvent any bias due to prostate pathology. Our results show that the gene expression profiles of the three epithelial cell subpopulations are different (Figure 2A ). Gene expression in LSC med shares some similarity to basal/stem and to luminal cells ( Unsupervised cluster analysis of the microarray results segregated LSC med as a separate prostate cell population, different from luminal and basal/stem cells but closer to the former ( Figure 2C ). Further analysis of established markers proved that LSC med share some similarities with basal/stem and some with luminal cells (Figure 2D ; RT-qPCR validations in Figure 2E ). Certain luminal markers, e.g. Krt8, Krt18, and Krt19, were present in both luminal and LSC med , consistent with LSC med being similar to luminal cells ( Figure 2C ). Nevertheless, markers of mature (secretory) luminal cells (Pbsn, Msmb) were not expressed in LSC med . Several stem cell markers were expressed in LSC med , e.g. Tacstd2 (Trop2) and Cd44, implying some similarity to basal/stem cells, but traditional basal markers (Krt5, Krt14, and Trp63) were not expressed in LSC med . Importantly, LSC med did not express Nkx3.1 ( Figure 2E ), implying that LSC med and CARN cells [6] are distinct epithelial cell populations.
In summary, LSC med express genes typical of both luminal and basal/stem cells but represent a distinct, newly identified epithelial cell entity.
The LSC med -specific gene expression signature is conserved across mouse models Figure 1A ), we reasoned that if the LSC med identity is conserved in a cancer context, the gene expression profile of unsorted Pten pc−/− mouse prostates should reflect an enrichment of LSC med -specific genes. We tested this hypothesis by using the LSC med signature generated above to query two independent transcriptomic datasets of Pten pc−/− mouse prostate tissue relative to WT (GSE46799 and GSE46473) [23, 24] . Both analyses revealed a strong overlap of LSC med -specific genes with those differentially expressed in Pten pc−/− mice versus WT. Of a total of 92/93 LSC med -specific genes present in these two datasets, 84/85 were concordantly up-or down-regulated in both unsorted Pten pc−/− prostates and sorted WT LSC med ( Figure 3B -D and supplementary material, Figure S2A -C). This strongly supports the notion that the LSC med signature is intrinsic to these cells and independent of the prostate pathological status.
To confirm this hypothesis, we selected 13 genes from the LSC med signature and compared their actual level of expression in sorted cell populations from WT, premalignant Pb-PRL, and malignant Pten pc−/− prostates by RT-qPCR ( Figure 3E and supplementary material, Figure S2D ). In the three models, significant up-regulation of these genes was observed in LSC med compared with basal/stem and luminal cell populations. Importantly, castration did not affect this population-specific expression pattern, even when the absolute expression levels varied post-castration (e.g. Psca). For some genes (e.g. Reg3b, Reg3g), a slight up-regulation was observed in the basal/stem compartment which nevertheless remained lower than in LSC med . Altogether, this analysis identified a unique gene expression signature of LSC med that is conserved irrespective of the pathophysiological and androgen signalling status of the prostate.
Cytokeratin 4 is a protein marker for LSC med before and after castration Cytokeratins are conventionally used to distinguish basal/stem from luminal prostate cells. Since the LSC med signature included CK4 (Krt4, Figure 3A , E), we aimed to use CK4 as a protein marker to identify LSC med on tissue slides. To confirm that CK4 protein expression was specific for LSC med , we immunostained Figure S1 ) were more restricted in size than those used for analysis (shown in Figure 1 co-expressed CK8, but not CK5, proteins ( Figure 4A ), consistent with gene expression studies ( Figure 2D, E) .
In tissue sections of intact prostates, we detected CK4 + cells that increased in frequency from WT to Pb-PRL and to Pten pc−/− tissue ( Figure 4B ), consistent with FACS analyses (Figure 1) . In WT prostates, CK4 + cells were restricted to the proximal regions of the gland (supplementary material, Figure S3 ). In contrast, in Pb-PRL mice, the CK4 + cells were distributed throughout the proximal and distal ductal regions (supplementary material, Figure S3 ), where p63 (Figure 1) , castration increased the frequency of CK4 + cells in WT and Pb-PRL prostates, while their prevalence remained high in Pten pc−/− mice ( Figure 4B ). Together, these analyses validated CK4 as a specific marker of LSC med in tissue sections, irrespective of the pathophysiological and androgen signalling status of the prostate.
LSC med of Pten pc−/− prostates highly proliferate and are tumour-initiating cells
To address the role of LSC med in cancer progression, we first analysed their proliferation in intact and castrated Pten pc−/− tumours using Ki-67 and CK4 co-immunostaining ( Figure 5A ). In intact mice, 18.3 ± 1.5% LSC med were Ki-67 + (> 20 000 CK4 + cells counted in randomly chosen fields from three animals). The mean proliferation index of CK4 + cells remained high 3 weeks after castration (14.6 ± 2.4%), although Ki-67 staining was more heterogeneous ( Figure 5A , c versus d). This suggests that some LSC med actively participate in cancer relapse. Very few proliferating LSC med could be detected in WT prostates before (< 0.7%) and even less after (< 0.15%) castration.
We next addressed the tumourigenic potency of Pten pc−/− LSC med using the in vivo prostate regeneration assay that was used to assess the tumour-initiating properties of Pten-deficient basal/stem cells [25] . All cell grafts involving LSC med (n = 3) or basal/stem cells used as a control (n = 2) generated palpable tumours ( Figure 5B ). The histomorphology of prostatic structures generated from LSC med ( Figure 5C , a-h) was comparable to carcinoma in situ with focal micro-invasion (red arrows in Figure 5C , c-f), prostate intraepithelial neoplasia (PIN), and extended atrophic, cystic glands. The histomorphology of grafts generated from basal/stem cells ( Figure 5C , i-k) was comparable to high-grade PIN lesions, with some foci of carcinoma in situ but no sign of micro-invasion. Immunofluorescence experiments showed the presence of basal/stem (CK5 + ), luminal (CK8 + ), and LSC med (CK4 + /CK8 + ) cells in tumours generated from LSC med ( Figure 5C , h) and basal/stem cells ( Figure 5C, k) . The micro-invasion phenotype observed in some non-atrophic irregular glands of LSC med grafts was associated with the absence of a basal cell layer ( Figure 5C , b, c, e, f), while the latter was mostly present in non-invasive glands of LSC med ( Figure 5C , h) and basal/stem ( Figure 5C , k) cell grafts.
Together, these experiments demonstrate that LSC med exhibit tumour-initiating properties and not only survive castration but also massively proliferate under these conditions of androgen depletion, supporting their key role in the progression to CRPC.
LSC
med display low androgen signalling but are sensitive to androgen manipulation
We hypothesized that the castration-tolerant properties of LSC med could reflect intrinsically low AR signalling. This was investigated using a published list of 148 androgen-responsive genes [22] . As expected in the WT prostate, luminal cells displayed an up-regulation of AR-activated genes and a down-regulation of AR-repressed genes ( Figure 6A ). In contrast, androgen signalling was markedly lower in LSC med , with AR-activated genes significantly down-regulated and AR-repressed genes up-regulated or unchanged relative to luminal cells ( Figure 6A ). In fact, based on androgen signalling, the hierarchical clustering places LSC med closer to basal/stem cells ( Figure 6B ), which, as expected, display the lowest levels of AR signalling activation ( Figure 6A and supplementary material, Figure S4 ).
The intrinsically low androgen signalling of LSC med likely explains why they tolerate androgen deprivation. This phenotype was not due to the lack of AR expression as LSC med of all the genotypes studied exhibited AR mRNA levels similar to those found in WT luminal cells ( Figure 6C ). However, the cytoplasmic AR staining observed in LSC med (identified by CK4 + staining on serial sections and circled with dashed lines in the right panels of Figure 6D ) contrasted with the exclusively nuclear AR staining observed in mature luminal cells (black arrows). This reduced nuclear AR translocation in LSC med (especially marked in Pb-PRL prostates) confirms the intrinsically low AR signalling activation in this cell population. Castration further down-regulated AR-activated genes that were expressed at detectable levels before castration in LSC med (Mme, Fkbp5, and Msmb, taken as examples) without down-regulating AR levels ( Figure 6E ).
Together with our earlier findings that dihydrotestosterone stimulation of LSC med led to the loss of Sca-1 expression [9] , these results indicate that LSC med are sensitive to androgen manipulation.
LSC med are enriched in low androgen signalling contexts
Our previous findings showed that dihydrotestosterone induced the loss of Sca-1 expression in LSC med , suggesting that androgens stimulate their differentiation into mature luminal cells [9] . Hence, we hypothesized that the enrichment of LSC med and decrease in luminal cells in intact Pten pc−/− and Pb-PRL prostates compared with WT prostates (Figures 1 and 4) could reflect a block in LSC med differentiation into luminal cells due to decreased AR signalling in these models. Consistent with this hypothesis, several groups previously showed reduced AR output in intact Pten pc−/− prostates due to the down-regulation of AR expression and/or AR transcriptional activity [21, 22, 26] . This is in agreement with the AR cytoplasmic staining observed in Pten pc−/− LSC med , which represent the majority of cells in Figure S5A) ; and (ii) altered expression of several androgen-regulated genes denoting significantly lower AR signalling in sorted luminal cells from Pb-PRL compared with WT prostates (supplementary material, Figure S5B ).
To further challenge the involvement of decreased prostatic AR-signalling activity in LSC med enrichment, we investigated another established model of prostate cancer named Hi-Myc. These mice harbour the c-myc oncogene driven by the ARR2/probasin promoter [27] . We used an independently generated set of transcriptomic data (GSE53202) to establish that, as opposed to Pten-null and similar to WT prostates, AR signalling was mainly unaffected in Hi-Myc mouse prostates (supplementary material, Figure S6A , B). Consistent with our hypothesis, the FACS profiles of Hi-Myc prostates bearing adenocarcinomas showed no LSC med enrichment (supplementary material, Figure S6C, D) . Furthermore, the expression of LSC med signature genes in prostates from Hi-Myc mice was similar to that in WT mice, and markedly lower than that in Pten-null mice (supplementary material, Figure S6E , F), confirming a lack of LSC med accumulation in the Hi-Myc model. Together, these results show that LSC med enrichment prior to castration is specific to mouse models with decreased AR signalling (Pten pc−/− , Pb-PRL).
Discussion
CRPC remains a lethal disease, and the development of efficient therapeutic strategies requires a better understanding of the cellular and molecular mechanisms driving cancer recurrence. Here, we identify LSC med cells as an important therapeutic target because they have progenitor properties; they can regenerate tumours in host mice; they increase proportionally upon disrupted AR signalling; they withstand androgen blockade in vivo; and they massively proliferate after castration in a relevant model of CRPC.
This study challenges the conventional paradigm of searching for castrate-resistant cells based on 'basal/stem' versus 'luminal' markers [28] because the transcriptional profile of LSC med defines them as a third, distinct prostatic cell entity sharing markers of each. This is consistent with an intermediate position between a basal/stem and a mature luminal cell in the prostate lineage hierarchy and with their proposed role as luminal progenitors capable of forming organoids and spheres in vitro and tubule-like structures in vivo [9, 11] . The intermediate nature of LSC med is implied also by their proximal ductal location in WT prostate glands, where stem/progenitor cells are known to reside [29] .
The fact that they have overlapping markers of luminal and basal/stem cells adds further complexity to the interpretation of previous studies, where LSC med are likely to have been analysed together with basal/stem or with luminal cells. For example, sorting strategies using Sca-1, Trop2 or CD44 would result in their inclusion in the basal/stem population [25, [30] [31] [32] , whereas immunostaining or lineage tracing using CK8/18 would capture them as luminal cells [3, 33] . Also, in models with low AR signalling such as the widely used Pten pc−/− mouse, where they represent the bulk of the epithelia, LSC med will influence the isolation of pure basal/stem or luminal cell types depending on the markers used for selection.
As evidenced from our analysis involving four different mouse models, LSC med enrichment is linked with the intrinsic level of AR signalling activation in the prostatic tissue more than with malignancy per se, as illustrated by the lack of LSC med enrichment in Hi-Myc prostate adenocarcinomas. This finding is particularly relevant since the standard of care of prostate cancer is androgen deprivation, which should lead to LSC med accumulation. The molecular mediators that contribute to LSC med enrichment in low AR-signalling contexts remain to be established. Interestingly, a recent study suggested a role for prostatic inflammation in the amplification of progenitor-like luminal cells in the human prostate [34] . Both Pb-PRL [35] and Pten-null [21] prostates exhibit significant inflammation, which was further amplified by castration. The presence of various immune genes in the LSC med signature suggests their responsiveness to inflammatory signals. Further studies will elucidate the role of inflammation in regulating LSC med homeostasis. In the in vivo regeneration assay, Pten pc−/− LSC med generated micro-invasive lesions in glands devoid of a basal cell layer, reminiscent of what is observed in human prostate cancer. The fact that glands with a well-formed basal cell layer co-existed in the same graft suggests that LSC med may comprise cells displaying distinct stem-like properties. Of note, WT LSC med were shown to generate different types of organoids in vitro [11] . Although Pten pc−/− prostate tumours are referred to as castration-resistant, significant cell death and reduction of prostate volume are observed within the first days post-castration [21] . The unchanged prevalence of the different epithelial cell populations before and after castration in this model suggests that some LSC med subsets may be more tolerant to castration than others, leading to clonal expansion. Accordingly, we identified large clusters of highly proliferative CK4
+ cells in castrated Pten pc−/− prostates. This most probably reflects the mitogenic effect of cell-autonomous Akt signalling [22] and may be observed with other oncogenic pathways that emerge in androgen deprivation resistance [1] . Ultimately, as seen in WT, Pb-PRL, and Pten pc−/− mouse models, LSC med will evade androgen deprivation therapy regardless of their genetic makeup, highlighting the clinical implications of their castration resistance.
Although there is increasing evidence that epithelial cells exhibiting both luminal and stem/progenitor cell characteristics play a major role in prostate tumour progression [6] [7] [8] 34] , the study of these cells has been hampered by the lack of specific phenotypic markers. Figure S1 . Sequential gates and staining controls used for FACS sorting of prostate cell populations Figure S2 . The LSC med -specific gene-expression signature is conserved across mouse models 
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